<DOC>
	<DOCNO>NCT01733459</DOCNO>
	<brief_summary>This 2-arm , randomize , double-blind , double-dummy , control clinical study , 6 month treatment evaluate clinical metabolic efficacy DLBS3233 improve reproductive parameter evaluate safety DLBS3233 woman polycystic ovary syndrome compare metformin , active control .</brief_summary>
	<brief_title>Efficacy Safety DLBS3233 Subjects With Polycystic Ovary Syndrome ( PCOS )</brief_title>
	<detailed_description>There 2 group treatment ; group consist 62 subject treatment regimen : - Treatment I : 1 capsule DLBS3233 100 mg ( daily ) 1 placebo caplet Metformin XR ( twice daily ) - Treatment II : 1 caplet Metformin XR 750 mg ( twice daily ) 1 placebo capsule DLBS3233 ( daily ) 6 month treatment . Clinical examination evaluate efficacy investigational drug perform baseline every interval 1 month . Laboratory examination evaluate metabolic efficacy parameter ultrasonography ( USG ) examination perform baseline , Month 3rd , end study ( Month 6th ) . In addition , USG also perform 2 week Month 3rd ( Month 3.5th ) Month 5th ( Month 5.5th ) . Laboratory examination evaluate reproductive efficacy parameter ( reproductive hormone level ) safety , baseline Month 6th ( end study ) . General counseling lifestyle modification provide subject assign Nutritionist . All study subject follow lifestyle modification . Evaluation subject ' performance lifestyle modification conduct every follow-up visit Investigator , particularly baseline , Month 3rd , end study ( Month 6th ) Nutritionist .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Female subject reproductive age ( i.e . 1840 year ) Subject diagnosis polycystic ovary syndrome confirm two Rotterdam Criteria Subject insulin resistance define : HOMAIR &gt; 2.00 Pregnant lactate woman Subjects know Cushing 's syndrome , late onset congenital adrenal hyperplasia , androgensecreting tumor , uncontrolled thyroid disease , hyperprolactinemia Known current medical condition , , judge Investigator could jeopardize subject 's health interfere study evaluation , diabetes mellitus , uncontrolled hypertension , cardiovascular disease , acute chronic infection , know malignancy Impaired renal function ( serum creatinine level &gt; 1.5 ULN ) Impaired liver function ( serum ALT level ≥ 2.5 ULN ) Medicallyassisted weight loss medication surgical procedure Currently laparoscopic ovarian diathermy ( LOD ) Currently treatment vitro fertilization ( IVF ) technique Have regularly take medication affect insulin sensitivity well reproductive function ( i.e . ovulation , menstrual cycle ) , within ≤ 3 month prior screen Participating clinical trial within 30 day prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PCOS , DLBS3233 , metformin , oral anti-hyperglycemic agent</keyword>
</DOC>